At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 334 enrolled
Drug / intervention
GSK189075 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomized 12-week Study to Evaluate the Safety and Efficacy of GSK189075 Tablets vs Pioglitazone in Treatment Naive Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating GSK189075, pioglitazone, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 334 participants across 136 sites in 19 countries.
Detailed Summary
This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of investigational product and pioglitazone, compared to placebo, administered as monotherapy over 12 weeks in treatment naive patients with T2DM
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesArgentina, Bulgaria, Chile, Costa Rica, Czechia, Germany, Hungary, India, Latvia, Lithuania, Mexico, New Zealand, Peru, Poland, Puerto Rico, Romania, Russia, South Africa, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedJul 2007
Primary CompletionFeb 2008
TodayJul 2026
First PostedJul 12, 2007
Enrollment StartJan 23, 2007
Primary CompletionFeb 14, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 19.0 years ago
Interventions
GSK189075drug
Experimental Drug
pioglitazonedrug
Active Control
Placeboother
Placebo Comparator